Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

PROCEPT BioRobotics (PRCT) EBITDA Margin (2020 - 2026)

PROCEPT BioRobotics has reported EBITDA Margin over the past 7 years, most recently at 38.12% for Q1 2026.

  • Quarterly EBITDA Margin fell 252.0% to 38.12% in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 31.9% through Mar 2026, up 426.0% year-over-year, with the annual reading at 31.05% for FY2025, 966.0% up from the prior year.
  • EBITDA Margin was 38.12% for Q1 2026 at PROCEPT BioRobotics, up from 39.08% in the prior quarter.
  • Over five years, EBITDA Margin peaked at 25.19% in Q2 2025 and troughed at 121.04% in Q1 2022.
  • The 5-year median for EBITDA Margin is 58.21% (2024), against an average of 66.15%.
  • Year-over-year, EBITDA Margin skyrocketed 6169bps in 2022 and then crashed -1164bps in 2025.
  • A 5-year view of EBITDA Margin shows it stood at 119.42% in 2022, then soared by 47bps to 62.9% in 2023, then skyrocketed by 56bps to 27.44% in 2024, then plummeted by -42bps to 39.08% in 2025, then grew by 2bps to 38.12% in 2026.
  • Per Business Quant, the three most recent readings for PRCT's EBITDA Margin are 38.12% (Q1 2026), 39.08% (Q4 2025), and 25.47% (Q3 2025).